Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 3/2009

01-09-2009 | Review

Mononuclear cells in liver fibrosis

Authors: Fabio Marra, Sara Aleffi, Sara Galastri, Angela Provenzano

Published in: Seminars in Immunopathology | Issue 3/2009

Login to get access

Abstract

Fibrosis is a multicellular wound healing process, where myofibroblasts that express extracellular matrix components extensively cross-talk with other cells resident in the liver or recruited from the bloodstream. Macrophages and infiltrating monocytes participate in the development of fibrosis via several mechanisms, including secretion of cytokines and generation of oxidative stress-related products. However, macrophages are also pivotal in the process of fibrosis resolution, where they contribute to matrix degradation. T lymphocytes modulate the fibrogenic process by direct interaction with myofibroblasts and secreting cytokines. In general, Th2 polarized responses promote fibrosis, while Th1 cytokines may be antifibrogenic. NK cells limit the development of fibrosis and favor its resolution, at least in part via killing of fibrogenic cells. The possible role of NKT cells and B cells is emerging in recent studies. Thus, mononuclear cells represent a critical regulatory system during fibrogenesis and may become an appealing target for therapy.
Literature
1.
2.
Schuppan D, Ruehl M, Somasundaram R, Hahn EG (2001) Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21:351–372PubMedCrossRef
3.
Pinzani M, Failli P, Ruocco C et al (1992) Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 90:642–646PubMedCrossRef
4.
Rockey DC, Housset CN, Friedman SL (1993) Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 92:1795PubMedCrossRef
5.
Mann DA, Smart DE (2002) Transcriptional regulation of hepatic stellate cell activation. Gut 50:891–896PubMedCrossRef
6.
Parola M, Robino G (2001) Oxidative stress-related molecules and liver fibrosis. Journal of Hepatology 35:297–306PubMedCrossRef
7.
Duffield JS, Forbes SJ, Constandinou CM et al (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56–65PubMed
8.
Smedsrod B, De Bleser PJ, Braet F et al (1994) Cell biology of liver endothelial and Kupffer cells. Gut 35:1509–1516PubMedCrossRef
9.
Bouwens L, Baekeland M, De Zanger R, Wisse E (1986) Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology 6:718–722PubMedCrossRef
10.
Winwood PJ, Arthur MJ (1993) Kupffer cells: their activation and role in animal models of liver injury and human liver disease. Semin Liver Dis 13:50–59PubMedCrossRef
11.
Purohit V, Brenner DA (2006) Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 43:872–878PubMedCrossRef
12.
Maher JJ (1999) Leukocytes as modulators of stellate cell activation. Alcohol Clin Exp Res 23:917–921PubMed
13.
Shiratori Y, Geerts A, Ichida T, Kawase T, Wisse E (1986) Kupffer cells from CCl4-induced fibrotic livers stimulate proliferation of fat-storing cells. J Hepatol 3:294–303PubMedCrossRef
14.
Geerts A, Schellinck P, Bouwens L, Wisse E (1988) Cell population kinetics of Kupffer cells during the onset of fibrosis in rat liver by chronic carbon tetrachloride administration. J Hepatol 6:50–56PubMedCrossRef
15.
Friedman SL, Arthur MJ (1989) Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 84:1780–1785PubMedCrossRef
16.
Gressner AM, Zerbe O (1987) Kupffer cell-mediated induction of synthesis and secretion of proteoglycans by rat liver fat-storing cells in culture. J Hepatol 5:299–310PubMedCrossRef
17.
Gressner AM, Weiskirchen R, Breitkopf K, Dooley S (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7:d793–d807PubMedCrossRef
18.
Matsuoka M, Tsukamoto H (1990) Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 11:599–605PubMedCrossRef
19.
Marra F, Gentilini A, Pinzani M et al (1997) Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology 112:1297–1306PubMedCrossRef
20.
Pinzani M, Gesualdo L, Sabbah GM, Abboud HE (1989) Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fatstoring cells. J Clin Invest 84:1786–1793PubMedCrossRef
21.
Nieto N (2006) Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 44:1487–1501PubMedCrossRef
22.
Rivera CA, Bradford BU, Hunt KJ et al (2001) Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol 281:G200–207PubMed
23.
24.
Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N (2002) Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122:1399–1410PubMedCrossRef
25.
26.
Aleffi S, Petrai I, Bertolani C et al (2005) Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42:1339–1348PubMedCrossRef
27.
Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA (2002) Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35:762–771PubMedCrossRef
28.
Mencin A, Kluwe J, Schwabe RF (2009) Toll-like receptors as targets in chronic liver diseases. Gut 58:704–720PubMedCrossRef
29.
Seki E, De Minicis S, Osterreicher CH et al (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13:1324–1332PubMedCrossRef
30.
Huang H, Shiffman ML, Friedman S et al (2007) A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46:297–306PubMedCrossRef
31.
Guo J, Loke J, Zheng F, Hong F, Yea S, Fukata M, Tarocchi M, Abar OT, Huang H, Sninsky JJ, Friedman S (2009) Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49(3):960–968PubMedCrossRef
32.
Watanabe A, Hashmi A, Gomes DA et al (2007) Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46:1509–1518PubMedCrossRef
33.
Gabele E, Muhlbauer M, Dorn C et al (2008) Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 376:271–276PubMedCrossRef
34.
Pardo M, Budick-Harmelin N, Tirosh B, Tirosh O (2008) Antioxidant defense in hepatic ischemia-reperfusion injury is regulated by damage-associated molecular pattern signal molecules. Free Rad Biol Med 45:1073–1083PubMedCrossRef
35.
Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H (2005) Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 128:138–146PubMedCrossRef
36.
Inoue S, Egashira K, Ni W et al (2002) Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106:2700–2706PubMedCrossRef
37.
Boring L, Gosling J, Cleary M, Charo IF (1998) Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894–897PubMedCrossRef
38.
Gu L, Okada Y, Clinton SK et al (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275–281PubMedCrossRef
39.
Zamara E, Galastri S, Aleffi S et al (2007) Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol 46:230–238PubMedCrossRef
40.
Marra F, DeFranco R, Grappone C et al (1999) Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med 47:66–75PubMed
41.
Josse C, Boelaert JR, Best-Belpomme M, Piette J (2001) Importance of post-transcriptional regulation of chemokine genes by oxidative stress. Biochem J 360:321–333PubMedCrossRef
42.
Xu Y, Rojkind M, Czaja MJ (1996) Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat-storing cells. Gastroenterology 110:1870–1877PubMedCrossRef
43.
Marra F, Valente AJ, Pinzani M, Abboud HE (1993) Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest 92:1674–1680PubMedCrossRef
44.
Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y (1994) Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. J Leukoc Biol 55:120–126PubMed
45.
46.
Marra F, Romanelli RG, Giannini C et al (1999) Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 29:140–148PubMedCrossRef
47.
Kruglov EA, Nathanson RA, Nguyen T, Dranoff JA (2006) Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am J Physiol Gastrointest Liver Physiol 290:G765–771PubMedCrossRef
48.
Marra F, DeFranco R, Grappone C et al (1998) Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152:423–430PubMed
49.
Asselah T, Bieche I, Laurendeau I et al (2005) Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129:2064–2075PubMedCrossRef
50.
Muhlbauer M, Bosserhoff AK, Hartmann A et al (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125:1085–1093PubMedCrossRef
51.
Seki E, de Minicis S, Inokuchi S, et al (2009) CCR2 promotes hepatic fibrosis in mice. Hepatology, in press
52.
Schwabe RF, Bataller R, Brenner DA (2003) Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 285:G949–G958PubMed
53.
Fallowfield JA, Mizuno M, Kendall TJ et al (2007) Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 178:5288–5295PubMed
54.
Gehring S, Dickson EM, San Martin ME et al (2006) Kupffer cells abrogate cholestatic liver injury in mice. Gastroenterology 130:810–822PubMedCrossRef
55.
Roggin KK, Papa EF, Kurkchubasche AG, Tracy TF Jr (2000) Kupffer cell inactivation delays repair in a rat model of reversible biliary obstruction. J Surg Res 90:166–173PubMedCrossRef
56.
Harty MW, Huddleston HM, Papa EF et al (2005) Repair after cholestatic liver injury correlates with neutrophil infiltration and matrix metalloproteinase 8 activity. Surgery 138:313–320PubMedCrossRef
57.
Harty MW, Papa EF, Huddleston HM et al (2008) Hepatic macrophages promote the neutrophil-dependent resolution of fibrosis in repairing cholestatic rat livers. Surgery 143:667–678PubMedCrossRef
58.
Mitchell C, Couton D, Couty JP et al (2009) Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol 174:1766–1775PubMedCrossRef
59.
Martinez FO, Sica A, Mantovani A, Locati M (2008) Macrophage activation and polarization. Front Biosci 13:453–461PubMedCrossRef
60.
Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H (2009) Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol [Epub ahead of print].
61.
62.
Pesce JT, Ramalingam TR, Mentink-Kane MM et al (2009) Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 5:e1000371PubMedCrossRef
63.
64.
Casini A, Ricci OE, Paoletti F, Surrenti C (1985) Immune mechanisms for hepatic fibrogenesis. T-lymphocyte-mediated stimulation of fibroblast collagen production in chronic active hepatitis. Liver 5:134–141PubMed
65.
Shi Z, Wakil AE, Rockey DC (1997) Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 94:10663–10668PubMedCrossRef
66.
Czaja MJ, Weiner FR, Takahashi S et al (1989) Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology 10:795–800PubMedCrossRef
67.
Baroni GS, D'Ambrosio L, Curto P et al (1996) Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23:1189–1199PubMedCrossRef
68.
Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G, Friedman SL (1992) Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 16:776–784PubMedCrossRef
69.
Knight B, Lim R, Yeoh GC, Olynyk JK (2007) Interferon-gamma exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury. J Hepatol 47:826–833PubMedCrossRef
70.
Marra F, Choudhury GG, Abboud HE (1996) Interferon-gamma-mediated activation of STAT1alpha regulates growth factor-induced mitogenesis. J Clin Invest 98:1218–1230PubMedCrossRef
71.
Pockros PJ, Jeffers L, Afdhal N et al (2007) Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 45:569–578PubMedCrossRef
72.
Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N (1998) Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 28:1597–1606PubMedCrossRef
73.
74.
Wang SC, Ohata M, Schrum L, Rippe RA, Tsukamoto H (1998) Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 273:302–308PubMedCrossRef
75.
Thompson KC, Trowern A, Fowell A et al (1998) Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation In vitro. Hepatology 28:1518–1524PubMedCrossRef
76.
Nelson DR, Tu Z, Soldevila-Pico C et al (2003) Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38:859–868PubMed
77.
Coutinho HM, Acosta LP, Wu HW et al (2007) Th2 cytokines are associated with persistent hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis 195:288–295PubMedCrossRef
78.
Alves Oliveira LF, Moreno EC, Gazzinelli G et al (2006) Cytokine production associated with periportal fibrosis during chronic schistosomiasis mansoni in humans. Infect Immun 74:1215–1221PubMedCrossRef
79.
Farah IO, Mola PW, Kariuki TM, Nyindo M, Blanton RE, King CL (2000) Repeated exposure induces periportal fibrosis in Schistosoma mansoni-infected baboons: role of TGF-beta and IL-4. J Immunol 164:5337–5343PubMed
80.
Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA (2007) Immunopathology of schistosomiasis. Immunol Cell Biol 85:148–154PubMedCrossRef
81.
Cheever AW, Williams ME, Wynn TA et al (1994) Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol 153:753–759PubMed
82.
Wynn TA, Cheever AW, Jankovic D et al (1995) An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594–596PubMedCrossRef
83.
Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104:777–785PubMedCrossRef
84.
Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA (2001) Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 167:7017–7026PubMed
85.
Pesce J, Kaviratne M, Ramalingam TR et al (2006) The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 116:2044–2055PubMedCrossRef
86.
Safadi R, Ohta M, Alvarez CE et al (2004) Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127:870–882PubMedCrossRef
87.
Safadi R, Zigmond E, Pappo O, Shalev Z, Ilan Y (2007) Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int Immunol 19:1021–1029PubMedCrossRef
88.
Horani A, Muhanna N, Pappo O et al (2007) Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 292:G628–638PubMedCrossRef
89.
Inada S, Suzuki K, Kimura T et al (1995) Concentric fibrosis and cellular infiltration around bile ducts induced by graft-versus-host reaction in mice: a role of CD8+ cells. Autoimmunity 22:163–171PubMedCrossRef
90.
Lombardo L, Capaldi A, Poccardi G, Vineis P (1995) Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis. Int J Clin Lab Res 25:153–156PubMedCrossRef
91.
Panasiuk A, Prokopowicz D, Zak J, Wysocka J (2003) Peripheral blood T, B, and NK cells in relation to histological hepatitis activity and fibrosis stage in chronic hepatitis C. Hepatogastroenterology 50:178–182PubMed
92.
Muhanna N, Doron S, Wald O et al (2008) Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 48:963–977PubMedCrossRef
93.
Zeremski M, Petrovic LM, Chiriboga L et al (2008) Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48:1440–1450PubMedCrossRef
94.
Bonacchi A, Romagnani P, Romanelli RG et al (2001) Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 276:9945–9954PubMedCrossRef
95.
Lasagni L, Francalanci M, Annunziato F et al (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197:1537–1549PubMedCrossRef
96.
Petrai I, Rombouts K, Lasagni L et al (2008) Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 40:1764–1774PubMedCrossRef
97.
98.
Bonacchi A, Petrai I, Defranco RM et al (2003) The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 125:1060–1076PubMedCrossRef
99.
Ebert LM, Schaerli P, Moser B (2005) Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 42:799–809PubMedCrossRef
100.
Holt AP, Haughton EL, Lalor PF, Filer A, Buckley CD, Adams DH (2009) Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 136:705–714PubMedCrossRef
101.
Hong F, Tuyama A, Lee TF et al (2009) Hepatic stellate cells express functional CXCR4: Role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology 49(6):2055–2067PubMedCrossRef
102.
Kobayashi S, Seki S, Kawada N et al (2003) Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res 311:353–364PubMed
103.
Jiang G, Yang HR, Wang L et al (2008) Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner. Transplantation 86:1492–1502PubMedCrossRef
104.
Vinas O, Bataller R, Sancho-Bru P et al (2003) Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 38:919–929PubMed
105.
Winau F, Hegasy G, Weiskirchen R et al (2007) Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 26:117–129PubMedCrossRef
106.
Gao B, Jeong WI, Tian Z (2008) Liver: an organ with predominant innate immunity. Hepatology 47:729–736PubMedCrossRef
107.
108.
Shirachi M, Sata M, Miyajima I, Tanaka M, Tanikawa K (1998) Liver-associated natural killer activity in cirrhotic rats. Microbiol Immunol 42:117–124PubMed
109.
Tsuyuki S, Yamauchi A, Nakamura H et al (1998) N-acetylcysteine improves cytotoxic activity of cirrhotic rat liver-associated mononuclear cells. Int Immunol 10:1501–1508PubMedCrossRef
110.
Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130:435–452PubMedCrossRef
111.
WL RS, Radaev S, Jeong WI, Park O, Gao B (2007) Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol 293(4):G809–816CrossRef
112.
Melhem A, Muhanna N, Bishara A et al (2006) Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 45:60–71PubMedCrossRef
113.
HA MN, Doron S, Safadi R (2007) Lymphocyte-hepatic stellate cell proximity suggests a direct interaction. Clin Exp Immunol 148(2):338–347CrossRef
114.
Jeong WI, Park O, Radaeva S, Gao B (2006) STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44:1441–1451PubMedCrossRef
115.
Jeong WI, Park O, Gao B (2008) Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 134:248–258PubMedCrossRef
116.
Asseman C, Pancré V, Quatennens B, Auriault C (1996) Schistosoma mansoni-infected mice show augmented hepatic fibrosis and selective inhibition of liver cytokine production after treatment with anti-NK1.1 antibodies. Immunol Lett 54:11–20PubMedCrossRef
117.
Krizhanovsky V, Yon M, Dickins RA et al (2008) Senescence of activated stellate cells limits liver fibrosis. Cell 134:657–667PubMedCrossRef
118.
Bendelac A, Rivera MN, Park SH, Roark JH (1997) Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15:535–562PubMedCrossRef
119.
Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23:877–900PubMedCrossRef
120.
Geissmann F, Cameron TO, Sidobre S et al (2005) Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 3:e113PubMedCrossRef
121.
Kimura K, Nagaki M, Matsuura T, Moriwaki H, Kakimi K (2009) Pathological role of CD44 on NKT cells in carbon tetrachloride-mediated liver injury. Hepatol Res 39(1):93–15PubMedCrossRef
122.
Kahraman A, Barreyro FJ, Bronk SF et al (2008) TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology 47:1317–1330PubMedCrossRef
123.
Park O, Jeong WI, Wang L et al (2009) Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49:1683–1694PubMedCrossRef
124.
MG NTI, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A (2005) Attenuated liver fibrosis in the absence of B cells. J Clin Invest 115:2962–2965CrossRef
125.
Mosmann T (2000) Complexity or coherence? Cytokine secretion by B cells. Nature immunology 1:465–466PubMedCrossRef
126.
Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (2006) IL-13 signaling through the IL-13alpha(2) receptor is involved in induction of TGF-beta(1) production and fibrosis. Nat Med 12:99–106PubMedCrossRef
127.
Afford SC, Rhandawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH (1999) CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface FasL expression and amplifies Fas mediated hepatocyte death during allograft rejection. J Exp Med 189:441–446PubMedCrossRef
128.
Zhou X, Tan FK, Milewicz DM, Guo X, Bona CA, Arnett FC (2005) Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype". J Immunol 175:4555–4560PubMed
Metadata
Title
Mononuclear cells in liver fibrosis
Authors
Fabio Marra
Sara Aleffi
Sara Galastri
Angela Provenzano
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 3/2009
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-009-0169-0

Other articles of this Issue 3/2009

Seminars in Immunopathology 3/2009 Go to the issue

Review

Contribution of human hematopoietic stem cells to liver repair

Review

The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?

Review

Primary biliary cirrhosis

Review

Microanatomy of the liver immune system

Introduction

Old and rising stars in the lymphoid liver

Review

The immunobiology of primary sclerosing cholangitis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits